Rein Therapeutics, Inc.
Rein Therapeutics, Inc. (Nasdaq: RNTX) is a clinical-stage biopharmaceutical company developing therapies for orphan pulmonary and fibrotic diseases. Its lead candidate, LTI-03, is an inhaled peptide derived from caveolin-1 that is in Phase 2 development for idiopathic pulmonary fibrosis. The company’s pipeline also… From the company’s description.
Over the twelve months to Jun 30, 2026, Rein Therapeutics, Inc. reported a net loss of $49.76M. Operations used $18.83M in cash. In fiscal 2025, it reported a net loss of $49.87M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Rein Therapeutics, Inc. does
In the company’s own words
Rein Therapeutics, Inc. (Nasdaq: RNTX) is a clinical-stage biopharmaceutical company developing therapies for orphan pulmonary and fibrotic diseases. Its lead candidate, LTI-03, is an inhaled peptide derived from caveolin-1 that is in Phase 2 development for idiopathic pulmonary fibrosis. The company’s pipeline also includes LTI-01, a proenzyme studied for loculated pleural effusion, an epithelial sodium channel inhibitor program for cystic fibrosis, and a caveolin-1-related peptide program for systemic fibrosis; development of these programs is paused while Rein prioritizes LTI-03. Rein’s RENEW Phase 2 trial evaluates LTI-03’s safety, tolerability and efficacy in patients with idiopathic pulmonary fibrosis. The company does not operate its own manufacturing facilities and relies on third-party manufacturers for product candidates used in research and clinical trials. It licenses LTI-01 development and commercialization rights in Japan to Taiho Pharmaceutical. Rein changed its name from Aileron Therapeutics in January 2025. Its website is https://www.re therapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- AUSTIN, TX
- Fiscal year end
- December
- CIK
- 1420565
- SIC
- 2834
Financial performance, year by year
Fiscal 2017–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Rein Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Rein Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Rein Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Rein Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Rein Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”